Brenner; Malcolm K.

Patent Applications and Registrations

Patent applications and USPTO patent grants for Brenner; Malcolm K..The latest application filed is for "auto/allo-immune defense receptors for the selective targeting of activated pathogenic t cells and nk cells".

Company Profile

4.9.22

Brenner; Malcolm K. - Houston TX
Brenner; Malcolm K. - Bellaire TX

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
Compositions and methods for the treatment of HER2-expressing solid tumors Grant 11,266,726 - Wood , et al. March 8, 2	2022-03-08
Auto/allo-immune Defense Receptors For The Selective Targeting Of Activated Pathogenic T Cells And Nk Cells App 20220000920 - Mamonkin; Maksim ; et al.	2022-01-06
REPROGRAMMING CD4 T CELLS INTO CYTOTOXIC CD8 CELLS BY FORCED EXPRESSION OF CD8aB AND CLASS 1 RESTRICTED T CELL RECEPTORS App 20210361705 - Arber Barth; Caroline Eva ; et al.	2021-11-25
Methods for inducing selective apoptosis Grant 11,077,176 - Brenner August 3, 2	2021-08-03
Auto/allo-immune Defense Receptors For The Selective Targeting Of Activated Pathogenic T Cells And Nk Cells App 20210077530 - Mamonkin; Maksim ; et al.	2021-03-18
Cd5 Chimeric Antigen Receptor For Adoptive T Cell Therapy App 20200405811 - Mamonkin; Maksim ; et al.	2020-12-31
Oncolytic Virotherapy And Immunotherapy App 20200323932 - Suzuki; Masataka ; et al.	2020-10-15
CD5 chimeric antigen receptor for adoptive T cell therapy Grant 10,786,549 - Mamonkin , et al. September 29, 2	2020-09-29
Oncolytic virotherapy and immunotherapy Grant 10,716,818 - Suzuki , et al.	2020-07-21
Methods For Inducing Selective Apoptosis App 20200030421 - Brenner; Malcolm K. ; et al.	2020-01-30
TRANSGENIC c-MPL PROVIDES LIGAND-DEPENDENT CO-STIMULATION AND CYTOKINE SIGNALS TO TCR-ENGINEERED T CELLS App 20200016207 - Arber Barth; Caroline Eva ; et al.	2020-01-16
Oncolytic Virotherapy And Immunotherapy App 20190374589 - Suzuki; Masataka ; et al.	2019-12-12
Adaptive Chimeric Antigen Receptor T-cell Design App 20190263928 - Watanabe; Norihiro ; et al.	2019-08-29
Compositions And Methods For The Treatment Of Her2-expressing Solid Tumors App 20180344828 - Wood; Lauren V. ; et al.	2018-12-06
Methods For Inducing Selective Apoptosis App 20180271961 - BRENNER; Malcolm K.	2018-09-27
Methods For Inducing Selective Apoptosis App 20180243385 - BRENNER; Malcolm K.	2018-08-30
Cd5 Chimeric Antigen Receptor For Adoptive T Cell Therapy App 20180104308 - Mamonkin; Maksim ; et al.	2018-04-19
Methods for inducing selective apoptosis Grant 9,393,292 - Brenner July 19, 2	2016-07-19
Methods For Inducing Selective Apoptosis App 20150366954 - Brenner; Malcolm K.	2015-12-24
Methods for inducing selective apoptosis Grant 9,089,520 - Brenner July 28, 2	2015-07-28
Methods For Inducing Selective Apoptosis App 20130323834 - BRENNER; Malcolm K.	2013-12-05
Engineered Cd19-specific T Lymphocytes That Coexpress Il-15 And An Inducible Caspase-9 Based Suicide Gene For The Treatment Of B-cell Malignancies App 20130071414 - Dotti; Gianpietro ; et al.	2013-03-21
Gene therapy expression of GHRH for increasing RBC count in subjects Grant 8,178,504 - Draghia-Akli , et al. May 15, 2	2012-05-15
Methods For Inducing Selective Apoptosis App 20110286980 - Brenner; Malcolm K.	2011-11-24
Plasmid mediated supplementation for treating chronically ill subjects App 20090170748 - Draghia-Akli; Ruxandra ; et al.	2009-07-02
Treating anemia in subjects by administration of plasmids encoding growth hormone releasing hormone Grant 7,241,744 - Draghia-Akli , et al. July 10, 2	2007-07-10
Plasmid mediated supplementation for treating chronically ill subjects App 20040057941 - Draghia-Akli, Ruxandra ; et al.	2004-03-25
Delivery of adenoviral DNA in a liposomal formulation for treatment of disease App 20030220284 - Yotnda, Patricia ; et al.	2003-11-27
Bi-spcific chimeric T cells App 20030148982 - Brenner, Malcolm K. ; et al.	2003-08-07

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.